高危前列腺癌幸存者的睾酮治疗:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项研究(1997-2017年),评估睾酮治疗与根治性治疗后高危前列腺癌幸存者复发风险的关系。
要点
- BCR率低于高危前列腺癌幸存者的预期率,但现有证据质量极低。
- 睾酮治疗在高危前列腺癌幸存者中仍为研究性治疗。
核心结论
- 睾酮治疗可能不增加根治性治疗后高危前列腺癌幸存者的BCR风险,但证据质量极低,结论不确定。
研究设计与样本
- 系统综述与荟萃分析,纳入13项研究(1997-2017年),主要分析109例高危前列腺癌患者。
主要发现
- 综述还评估了睾酮治疗的生化与症状效应。
关键数值与推荐
- 现有证据质量极低。
临床怎么用
- 睾酮治疗在高危前列腺癌幸存者中仍属研究性,不应作为常规临床实践。
局限性
- 现有证据质量极低,结论不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A systematic review and meta-analysis were performed to determine the relationship between testosterone therapy and the risk of recurrence in testosterone-deficient survivors of curatively treated high-risk prostate cancer. Primary outcome was the risk of biochemical recurrence (BCR) in 109 high-risk patients in 13 included studies (1997-2017). Biochemical and symptomatic effects of therapy were also reviewed. The BCR rate was 0.00 (0.00-0.05), lower than the expected rate for high-risk prostate cancer survivors, suggesting that testosterone therapy may not increase their BCR risk. However, this is uncertain as the available evidence is of very low quality. Testosterone therapy remains investigational in this group.
引用
- Teeling F, Raison N, Shabbir M, et al. Testosterone Therapy for High-risk Prostate Cancer Survivors: A Systematic Review and Meta-analysis. Urology. 2018. PMID: 30244116. doi:10.1016/j.urology.2018.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。